ASIT Biotech SA (ASIT):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ASIT Biotech SA (ASIT) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C3052
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:30
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ベルギー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ASIT Biotech SA (ASIT Biotech), formerly BioTech Tools SA is a clinical stage biopharmaceutical company that develops in-vitro and in-vivo biotech tools. The company develops and commercializes immunotherapy medicines for respiratory and food allergies using ASIT plus technology platform. Its ASIT plus active consist in broad panel of epitopes, which covers all the allergens present in the current immunotherapy products. ASIT Biotech’s products are used for grass pollen rhinitis, house dust mite asthma and peanut allergy. The company’s tools also develop vaccine adjuvants, treatment for allergies and immune response related diseases. It partners with pharmaceutical companies for licensing and/or co-development of pipeline candidates. The company provides ASIT plus technology platform serves various allergies. BioTech Tools is headquartered in Brussels, Belgium.

ASIT Biotech SA (ASIT) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ASIT Biotech SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ASIT Biotech SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ASIT Biotech SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ASIT Biotech SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ASIT Biotech SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
ASIT Biotech SA, Pharmaceuticals & Healthcare, Deal Details 10
Equity Offering 10
Asit Biotech Raises USD2.6 Million in Second Tranche of Private Placement of Shares 10
Asit Biotech Raises USD2.9 Million in Private Placement of Shares up on Exercise of Warrants 11
Asit Biotech Raises USD11 Million in First Tranche of Private Placement of Shares and Warrants 12
ASIT biotech Raises USD29.2 Million in IPO 13
ASIT Biotech to Raise USD9.2 Million in Private Placement of Shares 15
Debt Offering 16
ASIT Biotech Raises USD14.1 Million in Private Placement of Bonds 16
ASIT Biotech Raises USD4.6 Million in Private Placement of Bonds 17
ASIT Biotech SA – Key Competitors 18
ASIT Biotech SA – Key Employees 19
ASIT Biotech SA – Locations And Subsidiaries 20
Head Office 20
Recent Developments 21
Financial Announcements 21
Feb 12, 2018: ASIT Biotech 2017 Annual Results: Ongoing ASIT+ Products Development in Respiratory and Food Allergies 21
Sep 14, 2017: ASIT biotech presents its 2017 half-year results and provides update on its clinical programs 23
Apr 11, 2017: ASIT biotech Presents Its 2016 Annual Results and Recent Updates in Clinical Developments 24
Corporate Communications 26
Mar 20, 2017: ASIT biotech announces the appointment of Gerd Zettlmeissl as the Company’s new Chairman of the Board 26
Government and Public Interest 27
Jan 12, 2017: ASIT biotech receives 6 million euros in funding from the Walloon government for the development of new drug candidates to treat food allergies 27
Product News 28
04/04/2017: ASIT Biotech Announces that it Has Achieved the Primary Endpoint of the Phase I/IIa Clinical Trial with its hdm-ASIT+ Product Candidate for House Dust Mite Rhinitis 28
Clinical Trials 29
Jan 24, 2017: ASIT biotech announces Last Patient Last Visit in the phase IIa clinical study with its hdm-ASIT+ product candidate for treating house dust mite rhinitis 29
Appendix 30
Methodology 30
About GlobalData 30
Contact Us 30
Disclaimer 30

List of Tables
ASIT Biotech SA, Pharmaceuticals & Healthcare, Key Facts 2
ASIT Biotech SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ASIT Biotech SA, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ASIT Biotech SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ASIT Biotech SA, Deals By Therapy Area, 2012 to YTD 2018 8
ASIT Biotech SA, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Asit Biotech Raises USD2.6 Million in Second Tranche of Private Placement of Shares 10
Asit Biotech Raises USD2.9 Million in Private Placement of Shares up on Exercise of Warrants 11
Asit Biotech Raises USD11 Million in First Tranche of Private Placement of Shares and Warrants 12
ASIT biotech Raises USD29.2 Million in IPO 13
ASIT Biotech to Raise USD9.2 Million in Private Placement of Shares 15
ASIT Biotech Raises USD14.1 Million in Private Placement of Bonds 16
ASIT Biotech Raises USD4.6 Million in Private Placement of Bonds 17
ASIT Biotech SA, Key Competitors 18
ASIT Biotech SA, Key Employees 19

List of Figures
ASIT Biotech SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ASIT Biotech SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ASIT Biotech SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ASIT Biotech SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ASIT Biotech SA, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ASIT Biotech SA, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
ASIT Biotech SA, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ASIT Biotech SA, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[ASIT Biotech SA (ASIT):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • China Evergrande Group:企業のM&A・事業提携・投資動向
    China Evergrande Group - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's China Evergrande Group Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • Caixa Economica Federal:企業の戦略・SWOT・財務分析
    Caixa Economica Federal - Strategy, SWOT and Corporate Finance Report Summary Caixa Economica Federal - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • China Chemical & Pharmaceutical Co Ltd (1701):企業の財務・戦略的SWOT分析
    China Chemical & Pharmaceutical Co Ltd (1701) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • Sky Deutschland GmbH:企業の戦略・SWOT・財務情報
    Sky Deutschland GmbH - Strategy, SWOT and Corporate Finance Report Summary Sky Deutschland GmbH - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • CHC Group Ltd (HELIQ)-石油・ガス分野:企業M&A・提携分析
    Summary CHC Group Ltd. (CHC) is a commercial operator of medium and heavy helicopters that provides mission-critical services, search and rescue services, emergency and medical services, maintenance repair and overhauling services, helicopter parts sales and distribution, integrated logistics suppor …
  • Taisho Pharmaceutical Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Taisho Pharmaceutical Co Ltd (Taisho), a subsidiary of Taisho Pharmaceutical Holdings Co Ltd is a pharmaceutical company that develops, manufactures and markets a range of prescription pharmaceutical and self-medication drugs. The company offers products such as lipovitan D, riup, clarith, z …
  • Lucigen Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Lucigen Corp (Lucigen), a subsidiary of LGC Ltd, is a medical device company that discovers, manufactures, and commercializes molecular biology product. The company’s products comprise competent cells, nextgen seq, enzymes, cloning systems, PCR and amplification, cloning test kits and vector …
  • NeuroMetrix Inc (NURO):医療機器:M&Aディール及び事業提携情報
    Summary NeuroMetrix Inc (NeuroMetrix) is a healthcare company company that develops wearable medical technology and point of care test to manage chronic pain, nerve diseases, and sleep disorders. The company’s products include quell wearable pain relief device, quell health cloud, DPNCheck point-of- …
  • Intralot S.A. (INLOT):企業の財務・戦略的SWOT分析
    Intralot S.A. (INLOT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • GPS Source, Inc.:企業の戦略・SWOT・財務情報
    GPS Source, Inc. - Strategy, SWOT and Corporate Finance Report Summary GPS Source, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • HLL Lifecare Ltd:企業の製品パイプライン分析
    Summary HLL Lifecare Ltd (HLL) is a manufacturer of natural rubber latex condoms. The company offers products such as condoms, tubal rings, synthetic braided and coated absorbable suture, monofilament polydioxanone surgical suture, synthetic absorbable surgical suture, blood bank refrigerator, steri …
  • Pioneer Natural Resources Company:企業のM&A・事業提携・投資動向
    Pioneer Natural Resources Company - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Pioneer Natural Resources Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mer …
  • Repligen Corp (RGEN):企業の財務・戦略的SWOT分析
    Summary Repligen Corp (Repligen) operates as a bioprocessing life science company that develops and commercializes consumable products for manufacturing biological drugs. The company's products include Protein A affinity resins, Protein A ligands, ELISA kits, alternating tangential flow system, OPUS …
  • The Saudi Arabian Monetary Agency:企業の戦略的SWOT分析
    The Saudi Arabian Monetary Agency - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major p …
  • LG Corp (003550):企業の財務・戦略的SWOT分析
    LG Corp (003550) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …
  • Cipher Pharmaceuticals Inc (CPH):製薬・医療:M&Aディール及び事業提携情報
    Summary Cipher Pharmaceuticals Inc (Cipher) is a pharmaceutical company that develops skin care solutions. The company provides products such as actikerall, a topical solution indicated for the treatment of hyperkeratotic actinic keratosis; beteflam, a topical patch used for the treatment of mild to …
  • Systemair AB:企業の戦略・SWOT・財務情報
    Systemair AB - Strategy, SWOT and Corporate Finance Report Summary Systemair AB - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • TRACON Pharmaceuticals Inc (TCON):企業の財務・戦略的SWOT分析
    Summary TRACON Pharmaceuticals Inc (TRACON) is a biopharmaceutical company that develops and commercializes targeted therapies for cancer, age-related macular degeneration and fibrotic diseases. The company offers pipeline products such as TRC105, TRC102, TJ004309, TRC253, TRC694, and TRC205. Its le …
  • Turkiye Petrol Rafinerileri AS (TUPRS):企業の財務・戦略的SWOT分析
    Turkiye Petrol Rafinerileri AS (TUPRS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths a …
  • Genextra Spa-製薬・医療分野:企業M&A・提携分析
    Summary Genextra SpA (Genextra) is a pharmaceutical company that discovers and develops therapies for age-related and metabolic diseases. The company develops INT-747 for comb, mono therapy and diabetes, INT- 777 for metabolic syndrome; novel HDAC and HSP90 inhibitors for the treatment of cancer; mj …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆